REG - Creo Medical Group - US Reimbursement milestone for Speedboat procedure

Creo MedicalAnnouncement

28/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250528:nRSb3102Ka&default-theme=true

RNS Number : 3102K  Creo Medical Group PLC  28 May 2025

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

US Reimbursement milestone for Speedboat procedure

Further driving the roll-out of Creo's products

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces that the American Medical Association ("AMA")
Current Procedural Terminology (CPT(®)) Editorial Panel has issued its
Summary of Panel Actions confirming the establishment of two new Category I
CPT reimbursement codes for Endoscopic Submucosal Dissection ("ESD")
procedures - one for the upper gastrointestinal ("GI") tract and a second for
the lower GI tract.

 

The establishment of dedicated CPT codes provides a clear reimbursement
framework for U.S. healthcare providers to offer this advanced,
organ-preserving procedure to a broader patient population.  ESD is a
precision technique used to remove early-stage cancerous and pre-cancerous
lesions from the GI tract via an endoscope, eliminating the need for open
surgery or segmental organ removal. It allows for more accurate pathology and
has been associated with lower recurrence rates, faster recovery, and fewer
complications.

 

Creo Medical collaborated with a consortium of medical societies, key opinion
leaders and industry partners to gather peer-reviewed clinical data
illustrating improved clinical outcomes, and procedural data highlighting the
growing adoption of GI ESD procedures in the clinical community. This
collaborative effort demonstrated the safety, efficacy, and long-term benefits
of ESD, reinforcing its value in delivering better patient outcomes and
supporting its recognition through formal CPT coding.

 

It is estimated that around 5% of the U.S. population over the age of 50 could
potentially benefit from an ESD procedure. The data suggest that indications
potentially suitable for ESD treatment are diagnosed in between 5% and 10% of
the annual c.16 million U.S. colonoscopies performed. The establishment of
re-imbursement for lower GI ESD will open up access to this procedure to a
much larger proportion of these US patients with the clinical benefits
demonstrated.

 

The establishment of these reimbursement codes will also help drive continued
medical innovation by enabling and encouraging the use of next-generation
products such as Creo's Speedboat® UltraSlim, and Speedboat® Notch designed
specifically for ESD. All Creo's products are designed to empower clinicians
with greater precision, safety, and procedural efficiency for complex
endoscopic interventions.

 

For more information about ESD and Creo Medical's full portfolio of unique
advanced energy products, visit: www.creomedical.com/esd
(http://www.creomedical.com/esd)

 

Commenting, Craig Gulliford, Chief Executive Officer, said:

"This is a transformative moment for patients, clinicians, and the broader GI
community. The AMA's decision to establish dedicated CPT codes for ESD will
help remove barriers to access, enabling broader adoption of this advanced,
minimally invasive procedure in the U.S. We are proud to have worked alongside
leading societies, key opinion leaders, and industry partners to build the
clinical evidence base needed to support this milestone. With clearer
reimbursement pathways now in place, more patients will benefit from safer,
and more effective treatment options utilising Creo's range of products."

 

 

For further information please contact:

 

 Creo Medical Group plc                                                        www.creomedical.com
                                                                               (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                             Via Walbrook PR

 Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)         +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah

 Walbrook PR Ltd                      Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings        Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUCWAUPAPUM